Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -42.92% is 24% above its 5-year average of -56.58%, near the high end of its 5-year range (-358.62%–-15.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.29% above its 12-month average of -46.30%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -42.92%.
RETURN ON INVESTED CAPITAL (ROIC)
-42.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-46.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-90.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-56.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.29%
CURRENT VS 3Y AVG
+52.70%
CURRENT VS 5Y AVG
+24.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-20.41%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$261.43M
Return on Invested Capital (ROIC)
-42.92%
TTM Avg
-46.30%
3Y Avg
-90.74%
5Y Avg
-56.58%
Market Cap
$261.27M
Return on Invested Capital (ROIC)
-37.61%
TTM Avg
-32.44%
3Y Avg
-54.09%
5Y Avg
-56.96%
Market Cap
$262.92M
Return on Invested Capital (ROIC)
-59.50%
TTM Avg
-188.11%
3Y Avg
-308.62%
5Y Avg
-250.56%
Market Cap
$259.56M
Return on Invested Capital (ROIC)
-15.00%
TTM Avg
-11.69%
3Y Avg
-3.29%
5Y Avg
-2.92%
Market Cap
$259.49M
Return on Invested Capital (ROIC)
-37.64%
TTM Avg
-32.22%
3Y Avg
-29.09%
5Y Avg
-21.19%
Market Cap
$259.14M
Return on Invested Capital (ROIC)
-43.56%
TTM Avg
-66.27%
3Y Avg
-114.94%
5Y Avg
-104.61%
Market Cap
$259.12M
Return on Invested Capital (ROIC)
-39.76%
TTM Avg
-63.41%
3Y Avg
-63.96%
5Y Avg
-51.83%
Market Cap
$258.63M
Return on Invested Capital (ROIC)
-28.96%
TTM Avg
-103.16%
3Y Avg
-110.30%
5Y Avg
-171.09%
Market Cap
$264.25M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $261.43M | -42.92% | -46.30% | -90.74% | -56.58% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -37.61% | -32.44% | -54.09% | -56.96% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -59.50% | -188.11% | -308.62% | -250.56% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -15.00% | -11.69% | -3.29% | -2.92% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | -37.64% | -32.22% | -29.09% | -21.19% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | -43.56% | -66.27% | -114.94% | -104.61% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | -39.76% | -63.41% | -63.96% | -51.83% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -28.96% | -103.16% | -110.30% | -171.09% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -170.19% | -56.97% | -50.85% | -45.83% |
ROIC
-42.9%
ROE
-39.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -42.92% |
| 2026-03-31 | -33.17% |
| 2025-12-31 | -30.06% |
| 2025-09-30 | -70.14% |
| 2025-06-30 | -55.20% |
| 2025-03-31 | -44.80% |
| 2024-12-31 | -30.14% |
| 2024-06-30 | -358.62% |
| 2024-03-31 | -283.28% |
| 2023-12-31 | -175.46% |
| 2023-09-30 | -132.25% |
| 2023-06-30 | -100.77% |
| 2023-03-31 | -71.39% |
| 2022-12-31 | -85.35% |
| 2022-09-30 | -74.25% |
| 2022-06-30 | -63.70% |
| 2022-03-31 | -49.34% |
| 2021-12-31 | -38.19% |
| 2021-09-30 | -25.17% |
| 2021-06-30 | -15.05% |
| 2021-03-31 | -52.84% |
| 2020-12-31 | -27.90% |
